Antidiabetic Properties of Rose Hip

The purpose of this study is to determine whether daily intake of a drink containing rose hip powder reduces risk markers of type diabetes and cardiovascular disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Obesity Body Weight Glucose Intolerance Glucose Metabolism Disorders Hyperglycemia Metabolic Diseases Nutrition Disorders Nutritional and Metabolic Diseases Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Endocrinology Clinic, Lund University Hospital

Lund, SE-22185, Sweden

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

BMI > 30
willingness to participate in the study
willingness to comply with the daily intake of drinks and the recommended energy intake during the course of the study

Exclusion criteria

diabetes
previous or ongoing insulin treatment
abnormal thyroid status
abnormal liver status
abnormal kidney status
known gastrointestinal disorder
pregnancy
suspected allergy to ingredients of the drinks

Treatment and study plan

Rose hip

Dietary Supplement

40 g of rose hip powder daily for 6 weeks.

Sponsors and collaborators

Lead sponsor

Lund University

Other

Registry information

Official study title

Effects of Rose Hip Intake on Risk Markers of Type 2 Diabetes and Cardiovascular Disease: a Randomized Double-blind Cross-over Investigation in Obese Persons

Important dates

Study start: 2009
Primary completion: 2010
Study completion: 2011
First posted: Mar 16, 2011
Registry last updated: Mar 16, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed